In Vitro and In Vivo Effects of Adrenaline and Phentolamine on Platelet Function

Oreste Ponari; Emilio Civardi; Alessandro Megha; Mario Pini; Raffaele Poti’; Anton Giulio Dettori

doi:10.1055/s-0038-1648677

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 1978; 40(02): 428-438
DOI: 10.1055/s-0038-1648677

Original Article

Schattauer GmbH Stuttgart

In Vitro and In Vivo Effects of Adrenaline and Phentolamine on Platelet Function

Oreste Ponari

The Centro per le Malattie Emostatiche, Ospedali Riuniti di Parma, Parma, Italy

,

Emilio Civardi

The Centro per le Malattie Emostatiche, Ospedali Riuniti di Parma, Parma, Italy

,

Alessandro Megha

The Centro per le Malattie Emostatiche, Ospedali Riuniti di Parma, Parma, Italy

,

Mario Pini

The Centro per le Malattie Emostatiche, Ospedali Riuniti di Parma, Parma, Italy

,

Raffaele Poti’

The Centro per le Malattie Emostatiche, Ospedali Riuniti di Parma, Parma, Italy

,

Anton Giulio Dettori

The Centro per le Malattie Emostatiche, Ospedali Riuniti di Parma, Parma, Italy

› Author Affiliations

Abstract

PDF Download

Summary

In vitro and in vivo effects of adrenaline (ADR) on platelet aggregation, on platelet factor 3 (PF₃) availability and on platelet factor 4 (PF₄) release were studied in man. Inhibitory action of an alpha-blocker, phentolamine (PHEN) was investigated in the same conditions.

The threshold concentration (TC) of ADR inducing the typical two-phase response in aggregation tests when added to platelet-rich plasma (PRP) varied in different pools of plasma, but always induced an evident PF₄ release and increased PF₃ availability. A further increase in both parameters was obtained with higher concentrations but without any significant dose/response correlation.

Adding PHEN alone to PRP did not induce platelet aggregation or modify PF₄ release induced by stirring, but it reduced PF₃ availability. On the other hand, PHEN prevented the effects of ADR in different platelet tests, at appropriate concentrations.

Intravenous infusion of ADR lowered the TC, and increased PF₃ availability and PF₄ release. In vivo administration of PHEN, in contrast, increased TC and reduced PF₃ availability, while PF₄ remained unchanged.

PDF (1281 kb)

References

References
1 Brecher G, Cronkite EP. 1950; Morphology and enumeration of human blood platelets. Journal of Applied Physiology 3: 365
2 Bygdeman S, Johnsen Ø. 1969; Studies on the effect of adrenergic blocking drugs on catecholamine-induced platelet aggregation and uptake of noradrenaline and 5-hydroxytryptamine. Acta Physiologica Scandinavia 75: 129
3 De Gaetano G, Vermylen J, Verstraete M. 1972. Platelet factor 3. Properties and clinical significance In: Mannucci PM, Gorini S. (Eds) Platelet function and thrombosis. A review of methods Plenum Press; New York - London: p 159
4 Donati MB, Palester-Chzebowczyk M, Degaetano G, Vermylen J. 1972. Platelet factor 4. Properties and clinical significance In: Mannucci PM, Gorini S. (Eds): Platelet function and thrombosis. A review of methods Plenum Press; New York - London: p 173
5 Fiorentini P. Adesività e aggregazione piastrinica dopo carico di adrenalina nel normale e nell’iperteso. Proceedings of the 1st Meeting of the “Società Italiana per lo Studio dell’Emostasi e della Trombosi”.Parma 29.11.1971
6 Haft JL, Gershengorn K, Kranz PD, Oestreicher R. 1972; a Protection against epinephrine - induced myocardial necrosis by drugs that inhibit platelet aggregation. American Journal of Cardiology 30: 838
7 Haft JL, Kranz PD, Albert FJ, FANI K. 1972; b Intravascular platelet aggregation in the heart induced by norepinephrine. Microscopic studies Circulation 46: 698
8 Harada K, Zucker MB. 1971; Simultaneous development of platelet factor 4 activity and release of ¹⁴C-serotonin. Thrombosis et Diathesis haemorrhagica 25: 41
9 Hardisty RM, Hutton RA, Montgomery D, Rickard S, Trebilcock H. 1970; Secondary platelet aggregation: a quantitative study. British Journal of Haematology 19: 307
10 Kubisz P, Levy-Toledano S, Cronberg S, Pinkhas J, Caen J. 1970; Effect of phentolamine, an alpha-receptor blocking agent, on epinephrine, ADP and collagen-induced platelet factor 4 release and platelet aggregation. Revue Européenne d’Etudes Cliniques et Biologiques 15: 429
11 Libre EP, Cowan DH, Watkins Jr SP, Shulman NR. 1968; Relationship between spleen, platelets and factor Vili levels. Blood 31: 358
12 LüScher EF, Kaser-Glanzmann R. 1975; Platelet heparinneutralizing factor (platelet factor 4). Thrombosis et Diathesis haemorrhagica 33: 66
13 Macmillan DC. 1966; Secundary clumping effect in human citrated platelet-rich plasma produced by adenosine diphosphate and adrenaline. Nature (London) 211: 140
14 Mcclure PD, Ingram GI C, Vaughan Jones R. 1965; Platelet changes after adrenaline infusions with and without adrenaline blockers. Thrombosis et Diathesis haemorrhagica 13: 136
15 Mills DC B, Roberts CC K. 1967; Effects of adrenaline on human blood platelets. Journal of Physiology 193: 443
16 Mitchell JR A, Sharp AA. 1964; Platelet-clumping in vitro. British Journal of Haematology 10: 78
17 Niewiarowski S, Lipinski B, Farbiszewski R, Poplawski A. 1968; The release of platelet factor 4 during platelet aggregation and the possible significance of this reaction in hemostasis. Experientia (Basel) 24: 343
18 O’Brien JR. 1963; Some effects of adrenaline and antiadrenaline compounds on platelets “in vitro” and “in vivo”. Nature (London) 200: 763
19 O’Brien JR. 1964; Variability in the aggregation of human platelets by adrenaline. Nature (London) 202: 1188
20 O’Brien JR, Etherington MD. 1976; An inverse relation between platelet factor 4 in the platelet and in the plasma. Thrombosis and Haemostasis 36: 649
21 Ozge AH, Mustard JF, Hegardt B, Rowsell HC, Downie HG. 1963; The effect of adrenaline on blood coagulation, platelet economy and thrombus formation. Canadian Journal of Medical Association 88: 265
22 Ponari O, Cattabiani G, Mastandrea R, et Dettori AG. 1965; Les rapports entre le systéme nerveux et les phénomènes de coagulation et de fibrinolyse. Revue critique et contribution personnelle Hémostase 5: 379
23 Robison GA, Arnold A, Hartmann RC. 1969; Divergent effects of epinephrine and prostaglandin E₁ on the level of cyclic AMP in human blood platelets. Pharmacological Research Communications 1: 325
24 Rowsell HC, Hegardt B, Downie HG, Mustard JF, Murphy EA. 1966; Adrenaline and experimental thrombosis. British Journal of Haematology 12: 66
25 Rysanek K, Svehla C, Spankova H, Mlejnkova M. 1968 Comparison of the effect of various sympathicolytics on thrombocyte aggregation. Journal of Pharmacy and Pharmacology. 20.
26 Schwartz CJ, Ardlie NG. 1967; Catecholamines and platelet aggregation. Circulation Research 21 Suppl (Suppl. 03) 187
27 Spaet TH, Cintron J. 1965; Studies on platelet factor 3 availability. British Journal of Haematology 11: 269
28 Yamazaki H, Sano T, Odakura T, Takeuchi K, Matsumura T, Hosaki S, Shimamoto T. 1971; Appearance of thrombogenic tendency induced by adrenaline and its prevention by beta- adrenergic blocking agents, Nialamide and Pyridinolcarbamate. Thrombosis et Diathesis haemorrhagica 26: 251
29 Youssef A, Barkhan P. 1968; Release of platelet factor 4 by adenosine diphosphate and other platelet-aggregating agents. British Medical Journal 1: 746
30 Weiss HJ, Willis AL, Kuhn D, Brand H. 1976; Prostaglandin E₂ potentiation of platelet aggregation induced by LASS endoperoxide: absent in storage pool disease, normal after Aspirin ingestion. British Journal of Haematoloy 32: 257
31 Willis AL, Vane FM, Kuhn DC, Scott CG, Petrin M. 1974; An endoperoxide aggregator (LASS) formed in platelets in response to thrombotic stimuli. Prostaglandins 8: 453